Marc Tessier-Lavigne - Jan 3, 2023 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
Director
Signature
/s/**Marc Trevor Tessier-Lavigne
Stock symbol
REGN
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/5/2023, 03:16 PM
Previous filing
Nov 28, 2022
Next filing
Jun 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock +Grant/Award $0 +165 +7.27% $0.00 2,434 Jan 3, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) +Grant/Award $0 +1,929 $0.00 1,929 Jan 3, 2023 Common Stock 1,929 $725.89 Direct F2

Explanation of Responses:

Id Content
F1 Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2 On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.